Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.

ABSTRACT: Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to trastuzumab at diagnosis, and most patients with metastatic disease that initially respond to trastuzumab eventually progress (acquired resistance). Consequently, there is an urgent need to improve our knowledge of the mechanisms governing resistance, so that specific therapeutic strategies can be developed to provide improved efficacy. We generated new cell lines derived from BCCL through extended exposure to trastuzumab. Drug-conditioned populations were authenticated for their molecular profile and their resistance rate was determined. Heterogeneous HER2 amplificati

SUBMITTER: Zazo S 

PROVIDER: S-EPMC5126281 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature